ATyr Pharma Reports Positive Interim Results From Phase 2 Study Of Efzofitimod In SSc-ILD Patients

June 04, 2025 09:31 AM PDT | By EODHD

Google News:

ATyr Pharma Reports Positive Interim Results From Phase 2 Study Of Efzofitimod In SSc-ILD Patients — Image source: Kalkine Media

Recent News

Kalkine Valens Semiconductor Joins NYSE Composite Amid Rising Sector A...

Kalkine FinVolution Group’s Role in the NYSE Composite Landscape

CoreCard Co. Listed in Russell 1000 Index by Kalkine

S&P 500 Chart with Kalkine Key Trends and Market Movements

(RTTNews) - aTyr Pharma, Inc. (ATYR) announced encouraging interim data from its ongoing Phase 2 EFZO-CONNECT trial, evaluating efzofitimod in patients with systemic sclerosis-related interstitial lung disease or SSc-ILD. The interim analysis includes eight patients and shows early signs of clinical benefit, particularly in skin fibrosis outcomes. According to the company, three out of four patients with diffuse SSc-ILD who were treated with efzofitimod showed a clinically meaningful improvement in the modified Rodnan Skin Score or mRSS, a key measure of skin involvement. All treated patients showed either stable or improved mRSS at 12 weeks.

Additionally, early biomarker data showed potential reductions in inflammation and disease progression markers, including IFN-?, MCP-1, KL-6, and SP-D. The drug was also reported to be generally safe and well tolerated, with no serious treatment-related adverse events. The EFZO-CONNECT study is a 28-week, randomized, placebo-controlled trial involving patients with limited or diffuse SSc-ILD, aiming to enroll up to 25 patients. The primary endpoint is lung function improvement at 24 weeks, with skin and systemic symptoms also being assessed. Efzofitimod has received FDA Fast Track and Orphan Drug Designations in both the U.S.

and EU for SSc, and is also being evaluated in a Phase 3 trial for pulmonary sarcoidosis. aTyr plans to release further updates upon completion of the full trial. Currently, ATYR is trading at $5.32, down by 1.34 percent on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.